APA Citatie

Wen, P. Y., de Groot, J., Battiste, J. D., Goldlust, S. A., Garner, J., Simpson, J., . . . Cloughesy, T. (2019). P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O(6)-methylguanine-methyltransferase (MGMT) promoter status. Neuro Oncol.

Chicago Style citaat

Wen, P Y., J. de Groot, J D. Battiste, S A. Goldlust, J. Garner, J. Simpson, A. Olivero, en T. Cloughesy. "P05.06 Phase 2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3K/mTOR Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients With Unmethylated O(6)-methylguanine-methyltransferase (MGMT) Promoter Status." Neuro Oncol 2019.

MLA citatie

Wen, P Y., et al. "P05.06 Phase 2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3K/mTOR Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients With Unmethylated O(6)-methylguanine-methyltransferase (MGMT) Promoter Status." Neuro Oncol 2019.